https://mb.cision.com/Public/18595/3295277/b42a6f1a02dbee45_800x800ar.jpg
** UCB - sustaining growth, now and into the future
------------------------------------------------------------
=C2=B7 Revenue increased to =E2=82=AC 5.3 billion (+9%, +8% CER ) net sales=
to =E2=82=AC 5.1 billion (+8%, +7% CER)
=C2=B7 Underlying profitability (adj. EBITDA ) was =E2=82=AC 1.4 billion (+=
1%, -4% CER) or 27% of revenue
=C2=B7 R&D update: bimekizumab filed with FDA and EMA for psoriasis; timeli=
nes for late stage pipeline confirmed =E2=80=93 despite pandemic
=C2=B7 Financial outlook for 2021: Revenue expected to reach =E2=82=AC 5.45=
=E2=80=93 5.65 billion,=C2=A0adjusted EBITDA2 27 - 28% of revenue, Core EP=
S3 of =E2=82=AC 5.60 =E2=80=93 6.10 expected
=C2=B7 Outlook 2025: revenue of at least =E2=82=AC 6 billion and adj. EBITD=
A margin in the low to mid-thirties=C2=A0
UCB Full Year Report 2020:=C2=A0Brussels (Belgium), 25 February 2021 =E2=80=
=93 7:00 (CET) =E2=80=93 regulated information =E2=80=93=C2=A0
Note: English, Dutch and French pdfs at the end of the release
=E2=80=8B
https://mb.cision.com/Public/18595/3295277/8701f07960e79a28_800x800ar.png=
=E2=80=8B
Acquisitions and agreements=C2=A0
In October 2020, UCB acquired a new campus located in Windlesham, Surrey fo=
r its U.K. operations supporting cutting-edge research and development, ear=
ly manufacturing and commercialization of medicines. The acquisition reflec=
ts UCB=E2=80=99s commitment to retain the U.K. as one of its three global h=
ubs for research and development, alongside Belgium and the U.S.=C2=A0
In November 2020, UCB acquired Handl Therapeutics, a rapidly growing and tr=
ansformative gene therapy company based in Leuven, Belgium and entered into=
a new collaboration with Lacerta Therapeutics, a Florida based clinical st=
age gene therapy company. The new acquisition and collaboration will togeth=
er serve to rapidly accelerate UCB=E2=80=99s ambition in gene therapy.=C2=
=A0
Regulatory approvals=C2=A0
Vimpat^=C2=AE (lacosamide) - In October 2020, the Committee for Medicinal P=
roducts for Human Use (CHMP) of the European Medicines Agency (EMA) has ado=
pted a positive opinion on a license extension for the anti-epileptic drug =
Vimpat^=C2=AE as adjunctive therapy in the treatment of primary generalized=
tonic-clonic seizures (PGTCS) in adults, adolescents and children from 4 y=
ears of age with idiopathic generalized epilepsy =E2=80=93 approved in the =
European Union in December 2020.=C2=A0
In November 2020, the U.S. Food and Drug Administration (FDA) has approved =
Vimpat^=C2=AE as adjunctive therapy in the treatment of primary generalized=
tonic-clonic seizures in patients 4 years of age and older and Vimpat^=C2=
=AE injection for intravenous use in children four years of age and older.
R&D update=C2=A0
Bimekizumab - In September 2020, the U.S. Food and Drug Administration (FDA=
) and European Medicines Agency (EMA) accepted marketing application submis=
sions for bimekizumab for the treatment of adults with moderate to severe p=
laque psoriasis.=C2=A0
In July 2020, the Phase 3b study BE RADIANT, comparing bimekizumab to Cosen=
tyx^=C2=AE (secukinumab) for the treatment of adults with moderate-to-sever=
e plaque psoriasis, met all co- primary and ranked secondary endpoints, ach=
ieving significantly greater efficacy than secukinumab.=C2=A0
Dapirolizumab pegol: in August 2020, UCB and its partner, Biogen, included =
the first patients into the Phase 3 program with dapirolizumab pegol in pat=
ients with active systemic lupus erythematosus (SLE) despite standard-of-ca=
re treatment. First headline results are expected in H1 2024.
Rozanolixizumab: UCB is focusing its resources to new patient populations w=
ith autoantibody mediated neuro-inflammation and high unmet medical need. W=
ith these patients potentially benefitting from rozanolixizumab, UCB is pre=
paring the start of two clinical programs already during 2021 =E2=80=93 nex=
t to the ongoing Phase 3 studies in generalized myasthenia gravis (gMG) and=
immune thrombocytopenia (ITP). People living with chronic inflammatory dem=
yelinating polyneuropathy (CIDP) are a heterogenous and complex patient pop=
ulation, with approximately only 30% having detectable autoantibodies. Whil=
e the Phase 2a study in CIDP patients supports the conduct of a confirmator=
y clinical study, UCB decided to prioritize autoantibody mediated neuro-inf=
lammation indications over CIDP.
Bepranemab (UCB0107) Initiation of a Phase 2 study in Alzheimer=E2=80=99s d=
isease (AD) is planned for mid-2021, following the partnership agreement wi=
th Roche/Genentech. This will allow to evaluate the potential of bepranemab=
in a tau-mediated disease and subsequently explore options in different ta=
uopathy populations, including progressive supranuclear palsy (PSP).
In context with the pandemic, there are no changes to the expected timeline=
s for the late stage pipeline projects.
Net sales break-down by core product
https://mb.cision.com/Public/18595/3295277/ba592c913e843e56_800x800ar.png
https://mb.cision.com/Public/18595/3295277/802fd098eb7ab2f1_800x800ar.png=
=E2=80=8B=E2=80=8B
Nayzilam^=C2=AE (midazolam) Nasal Spray^CIV, a nasal rescue treatment for e=
pilepsy seizure clusters in the U.S. is successfully launched since Decembe=
r 2019 and reached net sales of =E2=82=AC 26 million.
Evenity^=C2=AE (romosozumab) had its first European launch in March 2020, f=
or the treatment of severe osteoporosis in postmenopausal women at high ris=
k of fracture, and reported net sales of =E2=82=AC 2 million, impacted by t=
he pandemic which significantly impedes outreach to new patient populations=
. Evenity^=C2=AE is being launched globally by Amgen, Astellas and UCB sinc=
e 2019, with net sales outside Europe reported by Amgen and Astellas.
2020 FY financial highlights
https://mb.cision.com/Public/18595/3295277/86ca0f614bac0608_800x800ar.png
=E2=80=8BRevenue in 2020 increased by 9% (+8% CER) to =E2=82=AC 5 347 milli=
on and net sales increased by 8% (+7% CER) to =E2=82=AC 5 052 million. Net =
sales before =E2=80=9Cdesignated hedging reclassified to net sales=E2=80=9D=
were =E2=82=AC5 022 million with a plus of 5% (+7% CER). This growth was d=
riven by the resilient UCB product portfolio - despite the pandemic.=C2=A0
Royalty income and fees were =E2=82=AC 96 million, plus 22% and benefitting=
from a one-time royalty recognized. Other revenue increased by 28% to =E2=
=82=AC 199 million due to higher contract manufacturing, milestones and oth=
er payments from R&D partners.=C2=A0
Gross profit reached =E2=82=AC 3 984 million, with a plus of 9% (+8% CER) a=
nd reflecting a slightly improved gross margin compared to 2019.=C2=A0
Operating expenses went up to =E2=82=AC 2 891 million (+14%; +16% CER) refl=
ecting=C2=A0
=C2=B7
10% higher marketing and selling expenses of =E2=82=AC 1 221 million - driv=
en by the launch of Cimzia=C2=AE in active non-radiographic axial spondyloa=
rthritis (nr-axSpA) in the U.S. and the launches in Japan and China, the la=
unch of Nayzilam=C2=AE in the U.S. and Evenity=C2=AE in Europe as well as l=
aunch preparations for bimekizumab for people living with psoriasis, ziluco=
plan and rozanolixizumab in myasthenia gravis and include expenses in conne=
ction with accelerated digital transformation in the pandemic context to be=
tter interactions, targeting and marketing
=C2=B7 23% higher research and development expenses of =E2=82=AC 1 569 mill=
ion =E2=80=93 which include for the first time the R&D expenses for the acq=
uired Ra Pharma, Engage Therapeutics and Handl Therapeutics R&D programs. O=
ngoing high investments in UCB=E2=80=99s progressing pipeline encompass fiv=
e late stage assets and include expenses in connection with digital transfo=
rmation for better patient experience and faster development time. Slightly=
lower R&D expenses due to the pandemic related to the recruitment pause in=
the first half 2020 were compensated by higher pandemic related expenses f=
or the safety of patients as well as ensuring patient recruitment in the se=
cond half of the year. Hence, the R&D ratio reached 29% in 2020 after 26% i=
n 2019.=C2=A0
=C2=B7 with +1% almost stable general and administrative expenses of =E2=82=
=AC 196 million, reflecting lower costs due to COVID-19 pandemic compensate=
d by digital business transformation activities and the contribution to the=
UCB fund (=E2=82=AC 5 million) in connection with COVID-19 pandemic.
Other operating income doubled to =E2=82=AC 95 million after =E2=82=AC 48 m=
illion in 2019 - driven by an income of =E2=82=AC 96 million in connection =
with the commercialization of Evenity^=C2=AE in collaboration with Amgen, a=
fter an income of =E2=82=AC 8 million in 2019, compensating mainly UCB=E2=
=80=99s marketing & selling as well as R&D expenses. UCB=E2=80=99s share to=
the total Evenity=C2=AE contribution has turned to positive earnings for t=
he first time. In 2019, =E2=80=9Cother=E2=80=9D operating items were impact=
ed by one-time positive contributions from investment grants, gain on dives=
titure and release of provisions.=C2=A0
Underlying operational profitability =E2=80=93 adjusted (recurring) EBITDA =
- reached =E2=82=AC 1 441 million (+1%, -4% CER) driven by continued revenu=
e growth and higher operating expenses, reflecting the investments into the=
future of UCB, namely into product launches and clinical development. The =
adjusted EBITDA ratio for 2020 (in % of revenue) reached 27%, from 29% in 2=
019.
Total impairment, restructuring and other income/expenses (formerly called =
=E2=80=9Cnon-recurring=E2=80=9D) were expenses of =E2=82=AC 122 million aft=
er =E2=82=AC 50 million in 2019. In 2020, this includes fees related to the=
acquisitions, restructuring expenses and an increase of provisions. In 201=
9, UCB strengthened its operating model to ensure maximum agility to meet t=
he growth expectations for the years ahead, leading to higher restructuring=
expenses.
Net financial expenses went down to =E2=82=AC 93 million from =E2=82=AC 107=
million in 2019, thanks to lower hedging costs, reduction of interest paya=
ble due to the repaid bond in March 2020, compensated by higher interest ex=
penses due to the debt financing of the Ra Pharma acquisition.
Income tax expenses were =E2=82=AC 119 million compared to =E2=82=AC 146 mi=
llion in 2019. The effective tax rate is 13% after 15% in 2019.
Profit amounted to =E2=82=AC 761 million (after =E2=82=AC 817 million), of =
which =E2=82=AC 732 million (after =E2=82=AC 792 million) is attributable t=
o UCB shareholders and =E2=82=AC 29 million (after =E2=82=AC 25 million) to=
non-controlling interests.
Core earnings per share, which reflect profit attributable to UCB sharehold=
ers, adjusted for the after-tax impact of to be adjusted items, the financi=
al one-offs, the after-tax contribution from discontinued operations and th=
e net amortization of intangibles linked to sales, reached =E2=82=AC 5.36 a=
fter =E2=82=AC 5.20 based on 189 million weighted average shares outstandin=
g (+1%)=C2=A0
Dividend - The Board of Directors of UCB proposes a dividend of =E2=82=AC1.=
27 per share (gross), +2%.
Outlook 2021: For 2021, UCB is aiming for revenues in the range of =E2=82=
=AC 5.45 =E2=80=93 5.65 billion thanks to the current core product growth a=
nd new patient populations being served, based on current assessment of the=
ongoing pandemic. UCB will continue to advance its late stage development =
pipeline and prepare upcoming launches to offer potential new solutions for=
patients.=C2=A0
Underlying profitability, adjusted EBITDA, is expected in the range of 27 -=
28% of revenue, reflecting the high R&D and marketing & sales investment l=
evels. Core earnings per share are therefore expected in the range of =E2=
=82=AC 5.60 =E2=80=93 6.10 based on an average of 189 million shares outsta=
nding. The figures for the outlook 2021 as mentioned are calculated on the =
same basis as the actual figures for 2020.=C2=A0
Outlook for 2025: For the first time UCB shares its growth ambition for 202=
5, despite upcoming patent expirations. Based on the strong product portfol=
io and the promising late-stage pipeline assets, UCB aims to lead in specif=
ic populations by 2025, creating value for patients now and into the future=
. Revenue in 2025 are expected to reach at least =E2=82=AC six billion and =
the underlying profitability (adj. EBITDA) should reach the low to mid-thir=
ties in percent of revenue.
Outlook 2021 & 2025: Based on UCB=E2=80=99s current assessment of the Covid=
-19 pandemic, UCB remains confident in the fundamental underlying demand fo=
r its products in the short-term and its prospects for long-term growth. UC=
B will continue to closely follow evolving COVID-19 pandemic and its conseq=
uences to the business environment diligently to assess potential near- and=
mid-term challenges. =C2=A0
Changes to the Board of Directors: In October 2020, UCB announced that at t=
he UCB Annual General Meeting on April 29, 2021, Evelyn du Monceau will hav=
e reached the statutory age limit and will step down as Chair and Director =
of the Board of UCB SA/NV. She will retire from the Board after 4 years as =
UCB=E2=80=99s Chair and over 35 years as UCB Board member.=C2=A0
The mandates of Albrecht De Graeve, Viviane Monges and Roch Doliveux will e=
xpire at the Annual General Meeting of April 29, 2021 (AGM 2021). Roch Doli=
veux informed the Board that, for personal reasons, he will not be candidat=
e for a further renewal of his mandate and will therefore leave the Board a=
nd UCB at the end of the term of his current mandate (i.e. the AGM 2021).
The Board will propose the following appointments to the AGM of April 29, 2=
021:
=C2=B7
The appointment of Mr. Stefan Oschmann as independent Director. If elected =
by the AGM 2021, Stefan Oschmann will become the Chair of the Board in repl=
acement of Mrs. Evelyn du Monceau.=C2=A0
=C2=B7 The appointment of Mrs. Fiona du Monceau as Director. If elected by =
the AGM 2021, she will become Vice Chair of the Board in replacement of Pie=
rre Gurdjian, who will stay in the Board as independent Director for the re=
mainder of his mandate. Fiona du Monceau is a representative of the Referen=
ce Shareholder and does not qualify as independent Director in accordance w=
ith the criteria of the 2020 Code.
=C2=B7 The appointment of Mr. Jonathan Peacock as independent Director. Jon=
athan Peacock meets all criteria of the 2020 Code and the Board to qualify =
as independent Director. If he is elected by the AGM 2021, Jonathan Peacock=
will become the Chair of the Audit Committee in replacement of Albrecht De=
Graeve.
=C2=B7 The renewal of the mandate of Albrecht De Graeve as Director. Albrec=
ht De Graeve will qualify as independent Director only for the first year o=
f his renewed mandate of 4 years (until the General Meeting of 2022). If re=
-elected, Albrecht De Graeve will stay as independent member of the Audit C=
ommittee for one additional year (until the General Meeting of April 2022).=
From the General Meeting of 2022 until the end of his mandate (2025) Albre=
cht De Graeve will remain non-independent member of the Board and will no l=
onger be member of the Audit Committee.=C2=A0
=C2=B7 The renewal of the mandate of Mrs. Viviane Monges as independent mem=
ber of the Board. If her mandate is renewed by the AGM 2021, Viviane Monges=
will remain independent member of the Audit Committee.=C2=A0
=C2=B7 In January 2021, UCB announced the cooptation of Professor Susan Gas=
ser as new member of UCB's Board of Directors, to be ratified at UCB=E2=80=
=99s next General Assembly on April 29, 2021. Prof Gasser replaces Professo=
r Alice Dautry who has reached the statutory age limit. The cooptation of P=
rof Susan Gasser was conducted in accordance with both the statutory rules =
of UCB and the BCCA. If approved at the next general assembly, Prof Gasser =
will qualify as an independent Board member and serve a 4-year mandate. She=
would also be appointed as a member of the Scientific Committee of the Boa=
rd.
The mandate of Price Waterhouse Cooper (PwC) will end at the AGM 2021. By a=
pplication of the European and Belgian mandatory rotation rules applicable =
to external auditors, PwC is no longer eligible for re-election as an exter=
nal Statutory Auditor. Based on a selection process overseen by the UCB Aud=
it Committee, the resultant recommendation and approval by the company=E2=
=80=99s works council, the Board will therefore propose the appointment of =
the audit firm Mazars Bedrijfsrevisoren - R=C3=A9viseurs d=E2=80=99Entrepri=
ses CVBA/SCRL as its statutory auditor for a mandate of 3 years (legal term=
) at the AGM of April 29, 2021.
Sustainability is UCB=E2=80=99s business approach and critical to long-term=
success and UCB=E2=80=99s contribution to society.
=C2=B7
In this context, the company made progress to enable access to its solution=
s for all patients who need them and started to report on the access perfor=
mance.=C2=A0
=C2=B7 As part of the broader aim to foster a positive working environment =
for all employees, UCB launched of a new health safety and well-being index=
.=C2=A0
=C2=B7 UCB continued to work to minimize its impact on the environment and =
to protect our planet=E2=80=99s health, working towards ambitious environme=
ntal targets.=C2=A0
2020 also saw a sustainability governance framework established comprised o=
f the new internal Sustainability Governance Committee and an External Sust=
ainability Advisory Board that gathers external experts to provide an outsi=
de perspective on UCB=E2=80=99s approach. As of 2020, UCB is a participant =
in the United Nations (UN) Global Compact and UCB committed to make the UN =
Global Compact and its principles an integral part of its business strategy=
, day-to-day operations and organizational culture.
Find the FY financial reports on UCB website: http://www.ucb.com/investors/=
Download-center=C2=A0
Today, UCB will host a conference call/video webcast at 08.00 (EST) / 13.00=
(GMT) / 14.00 (CET).
Details are available on=C2=A0https://www.ucb.com/investors/UCB-financials/=
Full-year-financial-results
For further information
Investor Relations
Antje Witte,
Investor Relations, UCB
T +32.2.559.9414
antje.witte@ucb.com=C2=A0
Isabelle Ghellynck,
Investor Relations, UCB
T+32.2.559.9588
isabelle.ghellynck@ucb.com=C2=A0
Global Communications
Laurent Schots,=C2=A0
Media Relations, UCB
T+32.2.559.9264
laurent.schots@ucb.com=C2=A0
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With more than 7 600 people in=
approximately 40 countries, the company generated revenue of =E2=82=AC 5.3=
billion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Follow =
us on Twitter: @UCB_news
Forward looking statements=C2=A0
This press release contains forward-looking statements including, without l=
imitation, statements containing the words =E2=80=9Cbelieves=E2=80=9D, =E2=
=80=9Canticipates=E2=80=9D, =E2=80=9Cexpects=E2=80=9D, =E2=80=9Cintends=E2=
=80=9D, =E2=80=9Cplans=E2=80=9D, =E2=80=9Cseeks=E2=80=9D, =E2=80=9Cestimate=
s=E2=80=9D, =E2=80=9Cmay=E2=80=9D, =E2=80=9Cwill=E2=80=9D, =E2=80=9Ccontinu=
e=E2=80=9D and similar expressions. These forward-looking statements are ba=
sed on current plans, estimates and beliefs of management. All statements, =
other than statements of historical facts, are statements that could be dee=
med forward-looking statements, including estimates of revenues, operating =
margins, capital expenditures, cash, other financial information, expected =
legal, arbitration, political, regulatory or clinical results or practices =
and other such estimates and results. By their nature, such forward-looking=
statements are not guarantees of future performance and are subject to kno=
wn and unknown risks, uncertainties and assumptions which might cause the a=
ctual results, financial condition, performance or achievements of UCB, or =
industry results, to differ materially from those that may be expressed or =
implied by such forward-looking statements contained in this press release.=
Important factors that could result in such differences include: the globa=
l spread and impact of COVID-19, changes in general economic, business and =
competitive conditions, the inability to obtain necessary regulatory approv=
als or to obtain them on acceptable terms or within expected timing, costs =
associated with research and development, changes in the prospects for prod=
ucts in the pipeline or under development by UCB, effects of future judicia=
l decisions or governmental investigations, safety, quality, data integrity=
or manufacturing issues; potential or actual data security and data privac=
y breaches, or disruptions of our information technology systems, product l=
iability claims, challenges to patent protection for products or product ca=
ndidates, competition from other products including biosimilars, changes in=
laws or regulations, exchange rate fluctuations, changes or uncertainties =
in tax laws or the administration of such laws, and hiring and retention of=
its employees. There is no guarantee that new product candidates will be d=
iscovered or identified in the pipeline, or that new indications for existi=
ng products will be developed and approved. Movement from concept to commer=
cial product is uncertain; preclinical results do not guarantee safety and =
efficacy of product candidates in humans. So far, the complexity of the hum=
an body cannot be reproduced in computer models, cell culture systems or an=
imal models. The length of the timing to complete clinical trials and to ge=
t regulatory approval for product marketing has varied in the past and UCB =
expects similar unpredictability going forward. Products or potential produ=
cts which are the subject of partnerships, joint ventures or licensing coll=
aborations may be subject to disputes between the partners or may prove to =
be not as safe, effective or commercially successful as UCB may have believ=
ed at the start of such partnership. UCB=E2=80=99 efforts to acquire other =
products or companies and to integrate the operations of such acquired comp=
anies may not be as successful as UCB may have believed at the moment of ac=
quisition. Also, UCB or others could discover safety, side effects or manuf=
acturing problems with its products and/or devices after they are marketed.=
The discovery of significant problems with a product similar to one of UCB=
=E2=80=99s products that implicate an entire class of products may have a m=
aterial adverse effect on sales of the entire class of affected products. M=
oreover, sales may be impacted by international and domestic trends toward =
managed care and health care cost containment, including pricing pressure, =
political and public scrutiny, customer and prescriber patterns or practice=
s, and the reimbursement policies imposed by third-party payers as well as =
legislation affecting biopharmaceutical pricing and reimbursement activitie=
s and outcomes. Finally, a breakdown, cyberattack or information security b=
reach could compromise the confidentiality, integrity and availability of U=
CB=E2=80=99s data and systems.=C2=A0
Given these uncertainties, you should not place undue reliance on any of su=
ch forward-looking statements. There can be no guarantee that the investiga=
tional or approved products described in this press release will be submitt=
ed or approved for sale or for any additional indications or labelling in a=
ny market, or at any particular time, nor can there be any guarantee that s=
uch products will be or will continue to be commercially successful in the =
future.
UCB is providing this information, including forward-looking statements, on=
ly as of the date of this press release and expressly disclaims any duty to=
update any information contained in this press release, either to confirm =
the actual results or to report or reflect any change in its forward-lookin=
g statements with regard thereto or any change in events, conditions or cir=
cumstances on which any such statement is based, unless such statement is r=
equired pursuant to applicable laws and regulations.=C2=A0
Additionally, information contained in this document shall not constitute a=
n offer to sell or the solicitation of an offer to buy any securities, nor =
shall there be any offer, solicitation or sale of securities in any jurisdi=
ction in which such offer, solicitation or sale would be unlawful prior to =
the registration or qualification under the securities laws of such jurisdi=
ction.
GenericFile
UCB Press Release FY 2020 NL (https://mb.cision.com/Public/18595/3295277/b7=
9fa470e2eeb2da.pdf) GenericFile
UCB Press Release FY 2020 FR (https://mb.cision.com/Public/18595/3295277/8a=
a5c01a31338861.pdf) GenericFile
UCB Press Release FY 2020 ENG (https://mb.cision.com/Public/18595/3295277/8=
527e42ee74d3e2b.pdf) Image
FY 2020 Chart 1 Feb 25 2021 (https://mb.cision.com/Public/18595/3295277/b5e=
75596fe40c9fc_org.png) Image
FY 2020 Chart 2 Feb 25 2021 (https://mb.cision.com/Public/18595/3295277/ba5=
92c913e843e56_org.png) Image
FY 2020 Chart 2 bis Feb 25 2021 (https://mb.cision.com/Public/18595/3295277=
/802fd098eb7ab2f1_org.png)
Image
FY 2020 Chart 3 Feb 25 2021 (https://mb.cision.com/Public/18595/3295277/86c=
a0f614bac0608_org.png)=0D
=0D
______________________=0D
If you would rather not receive future communications from UCB SA, please g=
o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x62301x1x6868579x24000=
x6&Email=3Dregnews%40symexglobal.com.=0D
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=